Neovii Pharmaceuticals AG, of Rapperswil, Switzerland, has granted Singapore-based Mundipharma Pte. Ltd. rights to develop and distribute its polyclonal antibody immunosuppressant, Grafalon (anti-human T-lymphocyte immunoglobulin), in China and Japan from the end of October.